SWP
CPRX

Strategic Wealth Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Strategic Wealth Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25 Hold
1
– – ﹤0.01% 1439
2025
Q4 		$23 Hold
1
– – ﹤0.01% 1427
2025
Q3 		$20 Hold
1
– – ﹤0.01% 1302
2025
Q2 		$22 Buy
+1
New +$24 ﹤0.01% 1130

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Strategic Wealth Partners's CPRX Position: Q1 2026 in Review

Strategic Wealth Partners held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 1 share worth $25. The position accounts for ﹤0.01% of the portfolio, ranked #1439.

Strategic Wealth Partners first reported a position in CPRX in Q2 2025 and has held it in 4 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Strategic Wealth Partners held 1 share of Catalyst Pharmaceutical worth $25 as of Q1 2026.
  • Strategic Wealth Partners left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of Strategic Wealth Partners's portfolio in Q1 2026, its #1439 holding.
  • Strategic Wealth Partners first reported a position in Catalyst Pharmaceutical in Q2 2025 and has held it in 4 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Strategic Wealth Partners's 13F filing for Q1 2026, filed 12 May 2026.